Division of Infectious Disease & International Medicine
College of Medicine - Department of Internal Medicine

Douglas A. Holt, MD, FACP, IDSA

Director, Division of Infectious Disease & International Medicine
Andor Szentivanyi Professor of Medicine, Division of Infectious Disease & International Medicine
Director, Hillsborough County Health Department, Tampa, FL
Biographical Sketch | Areas of Expertise | Current Research | Publications
Education
Residency, Internal Medicine Program, University of South Florida
Fellowship, Infectious Disease, University of South Florida, Tampa, FL
MD, University of South Alabama College of Medicine, Mobile, AL
BS, Davidson College, Davidson, NC
Contact Information
E-Mail: dholt@health.usf.edu
Phone: (813) 844-8297
FAX: (813) 844-7605

Biographical Sketch

Douglas A. Holt, MD, FACP, is Andor Szentivanyi Professor of Medicine and Director of the Division of Infectious Disease & International Medicine. He is the Director of the Hillsborough County Health Department (HCHD) which is the fourth largest of Florida’s Health Departments. Dr. Holt earned his medical degree from the University of South Alabama in 1984. He moved to Tampa where he completed his residency in Internal Medicine at the University of South Florida College of Medicine and his fellowship in Infectious Disease. He served as the Division’s first Chief Fellow and was also named the “Cuba Geigy Outstanding Resident.” After completing his fellowship, Dr. Holt joined the USF faculty in 1989.
 
Dr. Holt’s energy brought many changes to the Division. He pioneered collaborative work with the burn unit, solid organ transplant, BMT and trauma. He was recognized in 1990 and again in 1991 as “Best Teacher” by the Fellows. He guided the Fellowship Program and helped start the first HIV ward in Florida.

He has been Principal Investigator (PI) or co-PI on 57 research protocols, secured a $1 million HUD grant for a research facility build-out and authored 21 peer-reviewed publications. He is a graduate of the Public Health Leadership Institute Class 1. Prior to being appointed as the Director of the Hillsborough County Health Department he was the Chief of Medical Staff for two years. Dr. Holt was also the Acting Deputy State Health Officer in September of 2001 to February 2002 and helped direct the anthrax investigation in Lantana, Florida. He is an active member of many national, state and local organizations such as the American College of Physicians, Infectious Disease Society of America, Hillsborough County Medical Association, American Medical Association, Public Health Leadership Society, the Florida Medical Association, Florida Infectious Disease Society, Hillsborough Community College Foundation Board of Director’s, and The National Association of County & City Health Officials. In addition to the community activities, Dr. Holt has played an active role in many Florida Department of Health workgroups and committees, including the Fiscal Management Advisory Council, Fetal Infant Mortality Review Board, the Secretary’s Roundtable, and the Florida Association of County Health Officers.
 
As a Professor and Director, Dr. Holt convenes our public health conference, assists with RRC preparation, and actively attends on infectious disease rounds. He is acclaimed as an outstanding teacher by students, residents and fellows. One of his primary goals has been the integration of public health services and those of the university, a seamless system that would enhance patient care and avoid duplication of service. Through his efforts, the Florida Department of Health and USF have cooperative agreements that provide $600,000 a year to obtain professional medical services from university professors who serve in the critical public health positions of communicable disease and HIV research. He is actively pursuing affiliating the state IRB and the USF IRB.
 
He is most proud of fostering research. During his tenure as Professor and Health Department Director literally hundreds of research studies have been completed and grants submitted. He has been named “Outstanding Teacher in Infectious Disease” and has also been a charter member of the Cardiac Transplant and Liver Transplant Teams at Tampa General Hospital.   

Areas of Expertise

  • Pandemic Preparedness
  • Public Health Policy
  • Influenza

Current Research

Montero J, Holt DA. Multicenter, Double-Blind, Randomized, 2-Part, Dose Ranging Study to Compare the Safety, and Antiretroviral Activity of MK 1439 Plus TRUVADA Versus Efavirenz Plus Truvada in Antiretroviral Treatment-Naive, HIV-1 Infected Patients [Protocol: MK-1439-007-04 (Merck)], 2013-present

Wills T, Holt DA. A Multicenter, Randomized, Blinded, Placebo-Controlled Study to Evaluate the Safety of Maraviroc in Combination with Other Antiretroviral Agents in HIV-1Infected Subjects Co-Infected with Hepatitis C and/or Hepatitis B Virus [Protocol: A4001098], 2011 - 2012

Montero J, Holt DA.  A Multicenter, Randomized, Double Blind, Comparative Trial of Maraviroc + Darunavir/Ritonavir versus Emtricitabine/Tenofovir +Darunavir/Ritonavir for the Treatment of Antiretroviral-Naïve HIV Infected Patients with CCR5 Tropic HIV-1 [Protocol: A4001095], 2011 - Present

Emmanuel P, Holt DA.  IMPAACT 1077HS - HAART Standard Version of the PROMISE Study (Promoting Maternal and Infant Survival Everywhere), 2010 - Present

Casanas B, Holt DA.  A Phase 3 Randomized, Open-Label Study to Evaluate Switching from Regimens Consisting of a Ritonavir-boosted Protease Inhibitor and Two Nucleoside Reverse Transcriptase Inhibitors to Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate (FTC/RPV/TDF) Fixed-dose Regimen in Virilogically-Suppressed, HIV-1 Infected Patients [GS-US-264-0106], 2011 - Present

Wills T, Holt DA.  A Phase 3, Randomized, Double-Blind, Study to Evaluate the Safety and Efficacy of GS-9350-boosted Atazanavir versus Ritonavir-boosted Atazanavir.  Each Administered with Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naïve Adults.  [Protocol: GS-US-216-0114 (Gilead Sciences)], 2010 - Present

Wills T, Holt DA. Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Elvitegravir/Emrticitabine/Tenofovir Disoproxil Fumarate/GS-9350 versus Ritonavir-Booster Atazanavir Plus Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naïve Adults [Protocol: GS-US-236-0103 (Gilead Sciences)], 2010 - Present

Wills T, Holt DA. A Phse 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Elvitegravir/Emtricitavine/Tenofovir Disoproxil Fumarate/GS-9350 versus Favirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in HIV 1 Infected, Antiretroviral Treatment-Naïve Adults [Protocol: GS-US-236-0102 (Gilead Sciences)], 2010 - Present

Publications

Hauser RA, Furtado S, Cimino CR, Delgado H, Eichler S, Schwartz S, Scott BA, Nauert GM, Soety E, Sossi V, Holt DA, Sanberg PR, Stoessl AJ, Freeman TB. Bilateral human fetal striatal transplantation in Huntington’s disease, Neurology 58: 687-695, 2002

Ganguly R, Holt DA, Sinnott JT. Exposure of Medical Students to Body Fluids, The Journal of American College Health, 47:207, 1999

Freeman TB, Olanow CW, Hauser RA, Kordower JH, Holt DA, Borlongan CV, Sanberg PR. Human Fetal Tissue Transplantation, Neurosurgical Treatment of Movement Disorders, The American Association of Neurological Surgeons Chapter 13, 177-192, 1998

Nadler JP, Oehler RL, Holt DA. Update of Antiretroviral Therapy For HIV Infection, Infections in Medicine 15:113,1998

Holt DA, Nauert MG, Othberg AI, Randall TS, Willing AE, Widen RH, Hauser RA, Sanberg PR, Olanow CW, Freeman TB. Infectious Issues In Fetal Neural Transplantation, Cell Transplantation, 6:553, 1997

Holt DA, Larkin JA. Continuing Issues in Ventilator-Associated Pneumonia. Infections in Medicine, 12:12, 1995

Freeman TB, Olanow CW, Hauser RA, Nauert M, Smith DA, Borlongan CV, Sanberg PR, Holt DA, Kordower JH, Vingerhoets FJG, Snow BJ, Calne D, Gauger BS. Bilateral Fetal Nigral Transplantation into the Postcommissural Putamen in Parkinson's Disease, Annals of Neurology, 38:379, 1995

Abstracts

Holt DA, Co-Investigator. Gilead (GS-US-264-0106).  A Phase 3 Randomized, Open-Label Study to Evaluate Switching from Regimens Consisting of a Ritonavir-booested Protease Inhibitor and Two Nucleoside Reverse Transcriptase Inhibitors to Emtricitabine/Rilpivirine/ Tenofovir Disoproxil Fumarate 9FTC/RPV/TDF) Fixed-dose Regimen in Virologically-Suppressed, HIV-1 Infected Patients 

Holt DR, Co-Investigator. Pfizer (A4001098) Multicenter, Randomized, Blinded, Placebo-Controlled Study to Evaluate the Safety of Maraviroc in Combination with Other Antiretroviral Agents in HIV-1 Infected Subjects Co-Infected with Hepatitis C and/or Hepatitis B Virus

Holt DA, Co-Investigator. NICHD and NIAID (IMPAACT 1077HS) HAART Standard Version of the PROMISE Study (Promoting Maternal and Infant Survival Everywhere)

Holt DA, Co-Investigator. Cepheid (MRSA 123) Clinical Evaluation of the Xpert™ SA Nasal-CLIA Waived Assay for Nasal Swabs

Holt DA, Co-Investigator. A Phase IIIb, Randomized Open-Label Study to Evaluate the Safety and Efficacy of Single Tablet Regimen of Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate Compares with a Single Tablet Regimen of Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naïve Adults (Gilead GS-US-264-0110 - February 2011]

Holt DA, Co-Investigator.  A Phase 3 Randomized, Open-Label Study to Evaluate Switching from Regimens Consisting of a Ritonavir-boosted Protease Inhibitor and Two Nucleoside Reverse Transcriptase Inhibitors to Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate (FTC/RPV/TDF) Fixed-dose Regimen in Virologically-Suppressed, HIV-1 Infected Patients [Gilead GS-US-264-0106 February 2011]   

Holt DA, Co-Investigator.  An Open-label Trial with TMC278 25 mg q.d. in Combination with a Background Regimen Containing 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in HIV-1 Infected Subjects, Who Participated in TMC278 Clinical Trials [Protocol: TMC278-TiDP6-C222 - January 2011]

Search Google Scholar for Publications by Dr. Holt